Agios Pharmaceuticals, Inc. - AGIO STOCK NEWS

Agios Pharmaceuticals (Nasdaq: AGIO) announced its strategic vision for 2023 and beyond, focusing on pivotal trials in rare hematological diseases. They are on track for potential FDA approvals for PYRUKYND in thalassemia in 2025 and sickle cell disease in 2026. With a strong cash position, Agios aims to complete its ongoing programs and expand its pipeline towards cash-flow positivity. Key milestones include enrolling half of patients in ongoing studies and presenting data at the J.P. Morgan Healthcare Conference on January 11, 2023.

Agios Pharmaceuticals (Nasdaq: AGIO) announced the grant of inducement equity awards to newly appointed Chief Commercial Officer, Tsveta Milanova, effective January 3, 2023. The awards include a nonstatutory stock option for 135,682 shares at an exercise price of $27.53, restricted stock units for 25,426 shares, and performance stock units for 10,897 shares. The option vests over four years, while restricted stock units vest annually for three years. These grants comply with Nasdaq Listing Rule 5635(c)(4), indicating their significance in Milanova's employment.

Agios Pharmaceuticals, a leader in rare disease therapies, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT. The presentation will be accessible via a live webcast on the company’s website, with a replay available for at least two weeks afterward. Agios markets a first-in-class pyruvate kinase activator and is advancing a clinical pipeline focused on diseases like sickle cell disease and thalassemia. For more information, visit www.agios.com.

Agios Pharmaceuticals (NASDAQ: AGIO) presented data at the 64th ASH Annual Meeting, highlighting the long-term efficacy and safety of PYRUKYND (mitapivat) in adults with pyruvate kinase deficiency. The data indicates sustained improvements in hemoglobin levels and reduced transfusion burdens over periods up to 38 months.

These findings support ongoing studies in pediatric populations, with expectations of similar benefits in children. PYRUKYND has been recognized as the first oral treatment for this rare disease with FDA and EMA approvals, enhancing Agios's position in hematology.

Agios Pharmaceuticals (NASDAQ: AGIO) is actively enrolling patients in its Phase 3 ENERGIZE and ENERGIZE-T studies evaluating PYRUKYND^® (mitapivat) for adults with α- and β-thalassemia. The latest data presented at the 64th American Society of Hematology Annual Meeting demonstrated sustained improvements in hemoglobin concentrations and a well-tolerated safety profile for up to 72 weeks. Agios emphasizes the urgent need for new therapies for thalassemia, as current options are limited. An investor event will occur on Dec. 12, 2022, to discuss these developments further.

Agios Pharmaceuticals (Nasdaq: AGIO) announced the appointment of Tsveta Milanova as chief commercial officer, effective January 3, 2023. She will succeed Richa Poddar, who has held the position since 2016. Milanova brings over 20 years of experience in biopharmaceuticals, having worked at Alexion and Celgene. Her expertise in launching therapies for rare diseases is expected to enhance Agios' commercial strategy as the company seeks to expand its portfolio and market reach, particularly following the approval of its PK activator for adults with PK deficiency.

Agios Pharmaceuticals (NASDAQ: AGIO) will present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on December 7, 2022, at 11:25 a.m. ET. The presentation will be accessible via a live webcast on the company's website under the "Events & Presentations" section. A replay will be available for at least two weeks post-event. Agios focuses on therapies for rare diseases and is known for its first-in-class pyruvate kinase (PK) activator for adults with PK deficiency. The company is advancing its clinical pipeline for various hematological conditions.

Agios Pharmaceuticals has received EU marketing authorization for PYRUKYND® to treat pyruvate kinase (PK) deficiency in adults, marking it as the first disease-modifying therapy for this rare blood disorder. The approval follows positive results from pivotal studies, ACTIVATE and ACTIVATE-T, demonstrating significant clinical benefits, including increased hemoglobin levels and reduced transfusion needs. Agios aims to expand access via a global managed access program, and has plans to pursue further indications in pediatric patients and other diseases.

Agios Pharmaceuticals (NASDAQ: AGIO) presented significant clinical data at the 64th ASH Annual Meeting, highlighting the long-term benefits of PYRUKYND^® in adults with Pyruvate Kinase (PK) deficiency. Results showed improved hemoglobin levels, reduced transfusion needs, and better patient-reported outcomes. Additionally, new findings for the investigational PK activator AG-946 support its Phase 2 study in Myelodysplastic Syndromes (MDS)-associated anemia. An investor event is scheduled for Dec. 12, 2022, at 7 a.m. ET to discuss these developments.